Cadrenal Therapeutics Inc
NASDAQ:CVKD
Net Margin
Cadrenal Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
C
|
Cadrenal Therapeutics Inc
NASDAQ:CVKD
|
23.6m USD | N/A | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
722.9B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.3B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.2B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
185.9B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
161.1B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
198.9B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
136.3B USD |
13%
|
Cadrenal Therapeutics Inc
Glance View
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. The company is headquartered in Ponte Vedra, Florida and currently employs 1 full-time employees. The company went IPO on 2023-01-20. The firm is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (ESRD), and atrial fibrillation (irregular heartbeat) (AFib). The Company’s lead drug candidate, tecarfarin, is an anticoagulant that uses a drug design process which targets a different pathway than the most prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin is a Phase III-ready, vitamin K antagonist (VKA), taken once a day as an oral anticoagulant like warfarin. Tecarfarin was developed using a retrometabolic drug design process which targets a different metabolic pathway from the one targeted by the most prescribed anticoagulants. Tecarfarin was designed to follow a metabolic pathway distinct from the CYP450 pathway and is metabolized by both CYP450 and non-CYP450 pathways.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Cadrenal Therapeutics Inc's most recent financial statements, the company has Net Margin of 0%.
You don't have any saved screeners yet